石杉碱甲改善阿尔茨海默病患者智能障碍的效果评价

Clinical evaluation of huperzine A in improving intelligent disorder in patients with Alzheimer's disease

目的:为提高对阿尔茨海默病(Alzheimer'sdisease,AD)的认识,对61例AD患者进行临床综合分析,并给予石杉碱甲(商品名哈伯因)治疗,观察石杉碱甲治疗AD改善智能障碍的有效性。方法:将61例AD患者随机分为两组,治疗组口服石杉碱甲100μg,3次/d,对照组口服吡拉西坦片1.2g,3次/d,疗程均为3个月。在治疗前、治疗后1,2及3个月,采用简易精神状况检查法(MMSE)评分。结果:AD的临床主要表现为:女多于男,多缓慢起病,以记忆减退、行为与精神异常多见,CT/MRI证实脑萎缩。治疗1,2个月后,治疗组和对照组的MMSE评分犤分别为(22.6±3.4)与(19.2±3.3)分,(23.9±4.1)与(20.0±3.8)分犦差异有显著性意义(t=2.32,t=2.51,P均<0.05)。结论:石杉碱甲治疗轻、中度AD疗效较好。

AIM:To investigate the efficacy of huperzine A in improving cognition in patients with Alzheimer's disease(AD).METHODS:Sixty-one patients with AD were randomly divided into 2 groups:treatment group(treated with oral huperzine A(Hup) 100 μg 3 times every day for 3 months),and control group(treated with oral piracetam(naofukang) 1.2 g 3 times every day for 3 months).Mini-mental state examination(MMSE) was conducted before and 1,2 and 3 months after treatment.RESULTS:Clinical study showed that there were more female AD patients than male patients.The clinical manifestation of these patients included long incidence period,loss of memory,disruptive behavior and psychosis and brain atrophy proved by CT/MRI.The MMSE scores were 22.6±3.4 and 19.2±3.3 in the treatment and control group respectively 1 month after treatment(t=2.32,P< 0.05),and 23.9±4.1 and 20.0±3.8 respectively 2 months after treatment (t=2.51,P< 0.05).CONCLUSION:Huperzine A is effective in treating mild and moderate AD patients.